NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2.21 mln
Float1.28 mln
Earnings Date05/20/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
25.00
Transformational upside
Relative Strength
34
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-185
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Adial Pharmaceuticals is a Virginia-based drug development company working to help people overcome addiction and manage pain without opioids. Its most advanced treatment, AD04, is currently in late-stage clinical trials aimed at reducing harmful alcohol use. Founded in 2010, the company continues to expand its pipeline of potential therapies targeting a range of conditions.
